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ABSTRACT 
Crohn’s Disease (CD) is a chronic immune-mediated disorder with progressive and destruc-
tive course. Current guidelines on the treatment strategy still recommend a step-up approach 
with sequential prescription of corticosteroids and immunosuppressives. However, mounting 
evidences manifested that top-down therapy with early administration of anti-TNF or combi-
nation of immunosuppressives can achieve more rapid and higher rate of mucosal healing and 
has the potential of modifying the natural course of disease. Therefore, who is suitable to ac-
cept and when to start anti-TNF therapy have attracted the attention of gastroenterologists. 
And what benefit/risk can be expected from the two strategies should be carefully taken into 
account by clinicians. Age stratification, special patients, disease location and extension, ge-
netic and serologic testing are predictors of disease progression and complication and thus 
guide a personalized treatment approach in CD. A definition of early CD has been proposed 
to select an algorithm for treatment of moderate-to-severe CD with a suitable strategy. To 
date mucosal healing has been widely used, the Lémann score, which assesses the extent and 
severity of bowel damage at a specific time-point and over time, and is a new disability index 
for patients with CD, will be considered as a new endpoint for future studies of treatment 
strategies. Besides medicines of the two strategies, surgery, vaccine, Leukocytapheresis and 
stem cell therapy are all effective therapeutic approaches which lead to another thinking about 
what should they be putted in the conditional pyramid. However, we are trying to answer 
these questions. 
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TREATMENT STRATEGY FOR 
CROHN’S DISEASE 
Crohn’s Disease (CD), which is one 
type of inflammatory bowel disease (IBD), 
is an immune-mediated disorder that mainly 
affects any part of gastrointestinal tract. 
Asia is witnessing a rapid rise in occurrence 
of CD with time. In China, the recent inci-
dence and prevalence rates are 0.848/10(5) 
and 2.29/10(5) person/year, respectively 
(Ng et al., 2013; Zheng et al., 2010). The 
pathogenesis of CD mainly involves genet-
ic, environmental and immunological fac-
tors (Kaser et al., 2010). The disease has a 
chronic relapsing course with the period of 
acute exacerbation, remission or less active 
status and can finally lead to disability, sur-
geries, long-term hospitalization, poor qual-
ity of life and even death (Cosnes et al., 
2011). Current treatment, comprised of 
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medical and surgical procedures, is largely 
directed at symptom relief rather than mod-
ifying or reversing the underlying patho-
genic mechanism. The goal of treatment in-
cludes inducing remission (active treatment 
of acute disease) and maintaining remission 
(treatment of preventing relapse) (Mayberry 
et al., 2013). 
During the past decade, the develop-
ment of biologic therapies for CD has 
brought hope to patients and also led to an 
argument between step-up therapy and top-
down therapy. Many trials of biologic ther-
apies (including the combination of im-
munomodulators) are still in progress, but 
other than anti-TNF therapies, very few are 
likely to reach the clinic in the near future 
(De Vroey and Colombel, 2011). Step-up 
therapy is a traditional therapeutic approach 
which has still been recommended by cur-
rent guidelines (Mayberry et al., 2013; 
Dignass et al., 2010). It has focus on induc-
tion of a clinical remission using a progres-
sive intensification of treatment as the dis-
ease severity. 5-Aminosalicylates (5-ASA), 
corticosteroids, immunosuppressive drugs 
(e.g., Thiopurines) and biological agents 
(e.g., Infliximab, IFX) were used sequen-
tially to treat mild-to-severe CD (Bar-Meir, 
2009). But this strategy cannot positively 
induce mucosal healing and alter the natural 
history of CD (Lin et al., 2010). Therefore, 
mounting preliminary studies have showed 
that reversing the treatment paradigm from 
step-up approach to top down approach 
may remedy the defect (Lin et al., 2010; 
D'Haens et al., 2008; Present et al., 1999; 
Colombel et al., 2007; Ford et al., 2011). 
Top-down therapy refers to aggressive and 
early use of biological agents and immune 
modulators in order to avoid complications 
or surgery, decrease hospitalization and im-
proving quality of life (Fascì Spurio et al., 
2012; Blonski et al., 2011).Though this 
strategy is associated with better clinical 
outcomes, these drugs have rare but poten-
tially serious side effects (Lin et al., 2010; 
D'Haens et al., 2008; Present et al., 1999; 
Colombel et al., 2007; Ford et al., 2011). 
For the treatment of CD, there is no 
“one size fits all”. What gastroenterologists 
can do is to select a suitable treatment strat-
egy for every patient. So new questions oc-
curred: What is the rationale for selecting 
step-up therapy or top-down therapy? What 
benefit/risk can be expected from the two 
strategies? Is top down approach a good 
idea for all CD patients? At what points in 
the natural history of CD should one be 
started and ended? Is early therapy in CD 
only biologics and immunomodulators? 
However, we are trying to answer these 
questions. 
 
WHICH ONE IS BETTER? STEP-UP 
VERSUS TOP-DOWN THERAPY 
Step-up therapy is done first with less 
effective and limited systemic toxicity 
drugs, such as 5-ASA, antibiotics or gluco-
corticosteroids, mainly to suppress the 
symptoms of the disease. Then it moved to 
next step in non-responders by using more 
aggressive but higher toxicity immunosup-
pressive agents (azathioprine, mercaptopu-
rine and methotrexate) and biologic agents 
(antitumor necrosis factor antibody, anti-
TNF antibody, including infliximab, ada-
limumab, certolizumab pegol; monoclonal 
antibodies directed against the α4-integrin, 
natalizumab; monoclonal antibodies targets 
the α4β7-integrin, vedolizumab;etc.) in or-
der to both induce and maintain remission 
(Mayberry et al., 2013; Bar-Meir, 2009; 
D'Haens, 2010; Gionchetti et al., 2011). 
Although this strategy is usually effective 
for symptom control with less adverse 
events and can avoid overtreatment of low-
risk patients. The failure to optimize con-
ventional therapy can lead to patients’ be-
ing not receiving the optimal initial therapy 
before experiencing complications (struc-
turing or penetrating) and intestinal resec-
tions at final and being unnecessarily ex-
posed to potentially toxic and/or expensive 
biologic drugs, which is seriously impact 
their quality-of-lives (QOL) patients 
(Domènech et al., 2009; Taylor and Irving, 
2011). 
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The top-down strategy has been adopted 
for managing rheumatoid arthritis where 
there is a focus on treat-to-target to achieve 
early remission (Knevel et al., 2010). Les-
sons from rheumatoid arthritis can be trans-
lated to Crohn's disease. Recently many tri-
als (Mayberry et al., 2013; Lin et al., 2010; 
Kim et al., 2011; Yang et al., 2012; Xiao et 
al., 2012; Orlando et al., 2012) 
(Supplementary Table 1) have shown that 
patients who were administrated of immu-
nosuppressive or biologic agents in the ear-
lier phases of CD achieved less clinical re-
lapse, less steroid use, better mucosal heal-
ing, fewer hospitalizations, fewer complica-
tions and surgeries than those with the same 
disease that were further given those drugs. 
These findings have stimulated efforts in 
the field of CD towards to intensive and 
early top-down approach. However, the ev-
idence of wide use is still not strong 
enough, because the studies (Supplement-
ary Table 1) are somewhat susceptible to 
several methodological criticisms: 
(1) lack of large scale and multi-center 
trails; 
(2) often being open label studies; 
(3) not always giving sufficient considera-
tion of maintenance therapy especially 
in step-up group; and 
(4) always being short follow-up term. 
Several arguments exist against the top-
down approach in CD. First, Lin et al. 
(2010) and Kim et al. (2011) reported that 
approximately 30 % of patients might have 
been over treated by applying this therapy. 
Second, infliximab was found to be associ-
ated with 3-fold increase in malignancy and 
2-fold increase in serious infection in 
treatment of in rheumatoid arthritis (Bon-
gartz et al., 2006). Therefore, future thera-
pies of CD will be individualized and tar-
geted to optimize treatment outcomes and 
to reduce the disadvantages related to the 
two strategies. 
 
WHAT ARE THE LONG-TERM  
CONSIDERATIONS FOR PATIENT 
WITH CD? 
CD is a chronic and life-time of recur-
rent disease with flare-ups and remission, 
so we cannot just consider the short-term 
induction therapy. Long-term efficacy, 
safety and cost are main concerns of risk/ 
benefit assessment of different treatment 
strategies (Supplementary Figure 1). In 
step-up approach, infections associated with 
corticosteroids and lymphoma caused by 
azathioprine are commonly seen adverse 
events. In top-down approach, serious in-
fections, lymphoma and malignancies are 
side effects of anti-TNF agents and immu-
nosuppressives. In a more than 5 years of 
follow-up study, 36.273 patients (3.420 
infliximab and 2.853 other-treatments-only) 
have been enrolled into the TREAT regis-
try, mortality was similar for infliximab and 
other-treatments only patients (0.58 vs. 
0.59/100 patient-years of follow-up), an in-
creased risk of serious infection with inflix-
imab was observed (HR=1.43), and severity 
of CD at baseline (HR=2.24) and use of 
narcotic analgesics (HR=1.98) or predni-
sone (HR=1.57) carried higher risks for se-
rious infection (Lichtenstein et al., 2012). In 
a cohort study (1996–2009), data showed 
that use of anti-TNF with thiopurine and 
current use of thiopurine alone were associ-
ated with increased risk of lymphoma, in-
cluding diffuse large B-cell lymphoma 
(44 %), follicular lymphoma (14 %), and 
Hodgkin's disease (12 %) (Herrinton et al., 
2011). 
In addition, the economic burden of pa-
tients with CD is very high not only in Chi-
na but also in developed countries. Because 
patients must spend a lot of money on med-
icine, especially biologics, which most of 
them do not belong to the scope of medical 
insurance medicine. Meanwhile, some of 
patients with CD would experience disabil-
ity, loss of work productivity, surgery and 
hospitalization (Ordás et al., 2011). There-
fore, it is important to offset the high cost 
by selecting a suitable treatment strategy to 
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maintain long-term remission and prevent 
poor outcomes of CD. 
In conclusion, many studies have shown 
the direction of administrating biologics 
and immunomodulators, which offer an im-
portant clinical benefit for patients with se-
vere CD. But the risk-benefit ratio and cost-
effectiveness should be carefully taken into 
account by clinicians when treatment strat-
egies are established. 
 
WHICH IS THE TAILORED THERAPY 
FOR SPECIFIC SUBGROUP OF  
PATIENTS WITH CD? AGE SECTION, 
BIOLOGICAL MARIKERS OR LOCA-
TION OF DISEASE 
CD is a disease affecting all age groups, 
but there is a bimodal peak in incidence 
rates by age group with the first peak occur-
ring between the second and third decades 
of life (teenagers and young adults) and a 
second peak occurring between 55-59 years 
(Day et al., 2012; Quezada et al., 2011). In 
addition, we should accurately distinct el-
derly-onset CD and elderly people with dis-
ease starting at a younger age. A popula-
tion-based study showed that 1/20 incident 
cases of elderly-onset CD occurred in peo-
ple>60 years of age (Charpentier et al., 
2014). The heterogeneity of manifestations, 
a potentially insidious onset, the presence 
of overlapping features, extraintestinal 
symptoms and different features of every 
age stage can make the diagnosis and treat-
ment of CD difficult (Charpentier et al., 
2014; Dretzke et al., 2011). So we should 
take specific consideration to children, ado-
lescents, adults, and elderly when determin-
ing a treatment strategy (Supplementary 
Table 2) (Day et al., 2012; Krupoves et al., 
2011; Sherlock and Griffiths, 2012; Day et 
al., 2013; Sprakes et al., 2012; Assa et al., 
2013). For children and adolescents, opti-
mizing nutritional status and growth, mini-
mizing psychological concerns and possible 
side effects of treatment are critical consid-
erations of selecting a suitable treatment 
strategy (Mayberry et al., 2013; Day et al., 
2012; Charpentier et al., 2014; Krupoves et 
al., 2011; Sherlock and Griffiths, 2012; Day 
et al., 2013; Sprakes et al., 2012; Assa et 
al., 2012; Beaugerie et al., 2009; Setshedi et 
al., 2012; Cottone et al., 2011). For adults, 
optimizing conventional “step-up” therapy 
is still the recommendation, and the benefit 
of combination therapy has been demon-
strated by many studies. But new “top-
down” therapy is appropriate in moderate-
to-severe CD and more data supporting the 
efficacy and safety are needed before com-
bination therapy becomes the first choice 
treatment. To persuade the patient to quit 
smoking is also effective for treatment (La-
katos et al., 2013; Pithadia and Jain, 2011; 
Danese, 2012; Melmed et al., 2010). For the 
elderly, especially those>65 years, anti-
TNF therapy would be a dangerous choice 
and improving quality of care should be 
taken (Charpentier et al., 2014; Beaugerie 
et al., 2009; Setshedi et al., 2012; Cottone 
et al., 2011). 
In addition, the medical managements 
of pregnancy and post operation in CD re-
quire careful discussions with individual 
patients. During pregnancy, it is necessary 
to optimize disease control by treating ag-
gressively to prevent adverse outcomes 
(Mowat et al., 2011).The conventional me-
dicine (5-ASA) is safe in pregnancy and 
breast feeding (Selinger et al., 2012). Met-
ronidazole is considered safe after the first 
trimester (Mowat et al., 2011). In a recent 
population-based study, children born to 
mothers with CD got an increased risk of 
congenital abnormalities in women exposed 
to both corticosteroids and acetazolamide 
(Norgard et al., 2007). Methotrexate is 
strictly contraindicated because of the seri-
ous side effects of teratogenicity (Selinger 
et al., 2012). Infliximab and Adalimumab 
are rated as a second line medicine for 
pregnancy, which considered probably safe 
during the first two trimesters (Vermeire et 
al., 2012). There are need more evidence of 
the use of these during breast feeding. Ap-
proximately 80 % of patients with CD 
would finally accept operation, of whom 
70 % will require a further surgery (De 
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Cruz et al., 2013). Therefore, it is necessary 
to select appropriate treatment strategies to 
prevent postoperative recurrence. In a co-
hort study, step-up approach consisted of 
antibiotics, 5-ASA, thiopurine and metho-
trexate has been recommended (De Cruz et 
al., 2013). Lakatos and Lakatos (2010) de-
monstrated that anti-TNF agents may be 
appropriate for postoperative prevention 
and therapy in most severe cases. Savarino 
et al. (2012) further reported a case series of 
six patients who were given Adalimumab at 
the dose of 160/80/40mg every 2 weeks af-
ter resection for an ileocecal stricture cau-
sed by CD have been disease-free for about 
3 years after surgery on clinical, radiologi-
cal, and endoscopic/histological grounds 
(Crohn's Disease Activity Index ≤ 110 in all 
occasions). Such therapeutic benefits of 
strategies remain to be proven by further 
large controlled studies. 
There is accumulating evidence that 
current treatment strategy is guided by the 
disease location, severity, associated com-
plications and concurrent therapy taken by 
patients (Lin et al., 2010). Patient with CD 
involved of terminal ileum are strongly as-
sociated with an increased risk of stricture 
or penetrating behavior (Louis et al., 2010). 
Patients with rectal disease (92 %), colonic 
disease (41 %) and ileal disease (12 %) are 
associated with perianal disease (Hellers et 
al., 1980). They both lead to an increased 
risk of surgical resection (Lin et al., 2010, 
Hellers et al., 1980). In Loly’s study (Loly 
et al., 2008), the multivariate analysis 
showed that selected ileocolonic location 
needed steroids to treat the first flare. Cos-
tantino et al. (2012) indicated that admin-
istration of thiopurines among disease- and 
patient-related parameters a shorter disease 
duration, female gender and ileal disease in 
Crohn's patients had resulted in better re-
sponse. 
Although clinical parameters have some 
predictive value for prognosis and guiding 
treatment strategies in CD, their application 
still have some unsolved problems. The 
search for genetic polymorphisms and cy-
tokine profiles in CD has led to direction of 
potential predictors of prognosis and thus of 
identifying patients who should be treated 
more aggressively early on (top-down). 
Genome-wide association studies have 
identified approximately 71 CD-associated 
gene susceptibility loci and some of these 
have been studied their relation to CD phe-
notype and disease course (Franke et al., 
2010). The nucleotide oligomerization do-
main 2 (NOD2) or caspase-activating re-
cruitment domain 15 (CARD15) is known 
as a major susceptibility gene associated 
with worse CD prognosis and more likely 
to require surgical resection (Tamboli et al., 
2011). Recently, Plantinga et al. (2011) in-
dicated that variation in the autophagy gene 
ATG16L1 had been another major genetic 
susceptibility factor for CD and the risk 
variant of ATG16L1 is associated with an 
impaired induction of autophagy specifical-
ly after NOD2 engagement. And it is rele-
vant to IL-1β, IL-6 and TNF-α production 
in CD (Plantinga et al., 2011). These find-
ings suggest that patient’s genetic profile 
can assess risk of complicated disease 
which contributes to patient stratification 
and individualized care. Prieto-Pérez et al. 
(2013) demonstrated that gene polymor-
phisms can predict response to anti-TNF 
therapy in patients with immune disease, 
such as psoriasis (Ps), rheumatoid arthritis 
(RA) and CD. Gutiérrez et al. (2013) fur-
ther confirmed that intensified anti-TNF 
therapy is more frequent in patients with 
mutated NOD2/ ATG16L1-combined geno-
types. 
Current data have shown that genetic 
mutations could lead to alteration in the ex-
pression of some serological predictors, 
such as antibodies to microbial antigens 
(Tamboli et al., 2011). These antibodies in-
clude anti-Saccharomyces cerevisiae anti-
body (ASCA, glycan antibody), antibodies 
to the Escherichia coli outer-membrane 
point C (OmpC), the Pseudomonas fluo-
rescens CD-related protein [anti-CD related 
bacterial sequence (I2)] and the CBir1 fla-
gellin, which are mostly associated with 
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early disease onset CD, CD with earlier 
complications and relapsing CD (Beaugerie 
et al., 2012). So these can also be used as 
predictors of CD course to guide the selec-
tion of treatment strategy. 
In conclusion, age stratification, special 
patients, disease location and extension, ge-
netic and serologic testing all have potential 
to predict disease progression and compli-
cation, and thus response to medical thera-
pies, particularly biologic agents. In future, 
the combination of these would significant-
ly contribute to a personalized treatment 
approach in CD. 
 
WHEN TO INTRODUCE BIOLOGICAS 
AND WHERE IS THE ENDING POINT? 
The key to step-up therapy and top-
down therapy is whether earlier adminis-
trated with biologics or immunosuppressive 
agents. Population-based studies have 
shown that it is crucial to relate treatment 
instructions to the natural course of the dis-
ease for newly diagnosed CD. For the rea-
son that the heterogeneous clinical course 
associated with high risk of disease pro-
gression is a guide to identify the beginning 
point of early intervention with highly ef-
fective treatment strategies (Ordás et al., 
2011). Recently, a definition of early CD 
has been proposed to select an algorithm for 
treatment of moderate-to-severe CD with a 
suitable strategy (Supplementary Figure 2) 
(Ordás et al., 2011; Peyrin-Biroulet 2009; 
Burger and Travis, 2011; Yang et al., 
2011). It is defined as disease duration<2 
years and no previous use of immunosup-
pressive or TNF antagonists. And early sur-
gical resection is another common choice 
for serious patients (Ordás et al., 2011; 
Burger and Travis, 2011; Yang et al., 
2011). 
CD therapy is based on the primary 
goals of achieving every remission endpoint 
and ultimate goal of altering the long-term 
disease history course. The primary goals 
should include: 
(1) eliminate all symptoms related to a pa-
tient’s CD; 
(2) induction and maintenance of mucosal 
healing; 
(3) maintenance of normal gastrointestinal 
function; 
(4) avoidance of cumulative bowel da-
mage; 
(5) prevention of disability and surgery; 
and 
(6) improving patients’ QOL and reducing 
hospitalization (Ordás et al., 2011; 
Devlin and Panaccione, 2010). 
Nowadays, many studies confirmed that 
mucosal healing is becoming a valuable end 
point for accessing therapeutic efficacy in 
CD (Fascì Spurio et al., 2012; Blonski et 
al., 2011; Domènech et al., 2009). It has 
been widely used in clinical trials and basic 
researches to assess the severity of CD 
(Fascì Spurio et al., 2012; Blonski et al., 
2011; Domènech et al., 2009; Hébuterne et 
al., 2013; Danese and Peyrin-Biroulet, 
2012). Mucosal healing is considered to be 
the first step towards clinical symptom and 
to guide treatment strategies. Because it 
could measure changes in the disease, in-
cluding predicting the risk of clinical re-
lapse, occurrence of complications, require 
for surgical resection or re-operations and 
potential for cancer and mortality (Reenaers 
et al., 2012). However, mucosal healing 
could only reflect the external closure of 
fistulous tracts and not correspond to com-
plete healing of the penetrating bowel dis-
ease. Therefore, gastroenterologists are 
considering finding another end point of 
measuring the cumulative bowel damage. 
The International Program to develop New 
Indexes in Crohn's disease (IPNIC) group 
has conducted a new instrument, called the 
Crohn's Disease Digestive Damage Score 
(the Lémann score), to take into account 
damage location, severity, extent, progres-
sion, and reversibility by using computed 
tomography or magnetic resonance imaging 
enterography, and colonoscopy. The Lé-
mann score could be used as a more reliable 
endpoint to assess efficiency of various 
treatment strategies on the progression of 
bowel damage (Pariente et al., 2011a, b). 
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Hommes et al. (2012) suggest that we 
should change Crohn's disease management 
by applying new goals and indices, such as 
the Lémann score, to prevent disability and 
patient’s QOL. 
In conclusion, though gastroenterolo-
gists have proposed an algorithm for treat-
ment of early CD, there are still some modi-
fications to every individual patient. Even if 
mucosal healing has been widely used to 
date, the Lémann score, which assesses the 
extent and severity of bowel damage at a 
specific time-point and over time, and is a 
new disability index for patients with CD, 
will be considered as a new endpoint for fu-
ture studies of treatment strategies. 
 
IS EARLY THERAPY IN CD ONLY  
BIOLOGICS AND IMMUNOMODULA-
TORS? 
Though biologics and immunomodula-
tors have shared the main part of CD treat-
ment, and led to an argument between step-
up therapy and top-down therapy. There are 
many other effective therapeutic approach-
es, such as surgery, vaccine, Leukocy-
tapheresis (LCAP) therapy and stem cell 
therapy. 
The long term need of surgery in pa-
tients with CD could be decreased in the era 
of biologics (Jones and Finlayson 2010). In 
a population-based study, the surgery rate 
of patients newly diagnosed with CD in 
Cardiff between 1986 and 2003 at 5 years 
decreased significantly from 59 % (1986-
91) to 25 % (1998-2003) by induction of in-
fliximab (Jones and Finlayson, 2010). But 
surgery may still be a valid option in re-
spect to a refractory CD with complications 
or failure of the medical therapy. Different 
disease location and extension also appear 
to influence the need for surgery (Bernstein 
et al., 2012). In future, the minimally inva-
sive surgery, which aims at further reducing 
hospitalization and improving the cosmetic 
outcomes, will become standard clinical 
practice (Gardenbroek et al., 2012). 
Patients with CD are at increased risk of 
infection, partially due to the disease itself, 
but mostly because of treatment with im-
munosuppressive drugs (Gisbert et al., 
2013). Because vaccine can prevent many 
of infections, some clinical trials have been 
carried out to examine vaccine strategies 
for CD treatment (de Bruyn et al., 2012). 
Live vaccines are contraindicated in im-
munocompromised individuals, but inacti-
vated vaccines can be safely to patients un-
der immunotherapy (Rahier, 2013). But 
vaccination status should be checked and 
updated upon diagnosis of CD (Gisbert et 
al., 2013). 
LCAP is a recent modality for treatment 
of patients with CD, especially those refrac-
tory to conventional therapies (including 
steroids) (Fukunaga and Matsumoto, 
2012).The removal of circulating leuko-
cytes to suppress immunological response 
is primary aim of LCAP (Mitsuyama and 
Sata, 2009). In Japan, it has been accepted 
by authority government organizations. In a 
preliminary clinical trial of LCAP for CD 
patients, significant clinical efficacy togeth-
er with recovering peripheral immune re-
sponse has been reported (Fukunaga ans 
Matsumoto, 2012). It is predicted that 
unique non-pharmacological and non-
surgical strategy of LCAP has both effec-
tive and safety. And future strategies to op-
timize processing conditions and with or 
without combining biologics should now be 
studied (Muratov et al., 2012). 
Mesenchymal stem cells (MSCs) are the 
focus of intensive efforts worldwide by de-
veloping cell-based therapies for a diverse 
range of disease, including graft-versus-
host disease, Crohn's disease, myocardial 
infarction, and etc. Many basic and early 
clinical trails of MSCs therapy in CD have 
proven to be beneficial effects on mucosal 
healing and no result of toxicity or ectopic 
tissue growth (Duijvestein et al., 2010; Da-
lal et al., 2012). Local injection of MSCs is 
a novel and promising therapeutic strategy 
for refractory and fistulizing CD, offering 
hope to patients who have this notoriously 
difficult to treat and disabling manifestation 
of CD (Wood, 2011; Ciccocioppo et al., 
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2011). MSCs have the potentials of homing 
to injured gut tissues, actively participate in 
tissue repair, and regulating immune and in-
flammatory responses (Frenette et al., 
2013). So MSCs may serve as a candidate 
therapy for patients who have failed to re-
spond to biological therapy. Currently, 
scholars are making great efforts to trans-
late the science of MSCs into medicine 
(Bianco et al., 2013). 
In conclusion, the development of novel 
therapeutic strategies is leading to another 
thinking about what should they be putted 
in the conditional pyramid. 
 
CONCLUSIONS AND FUTURE  
DIRECTIONS 
CD which is a global epidemic disease 
with rapidly progressive course and disa-
bling complications attracted more attention 
to gastroenterologists all over the world. 
Conventional step-up approach with se-
quence use of low-toxicity drugs and novel 
top-down approach with early use of bio-
logicals are both effective to inducing re-
mission in the short term, but the latter one 
is more effective to maintain remission, de-
crease the rate of relapse, reduce admin-
istration of corticosteroids, prevent occur-
rence of complications and minimize opera-
tion in the long term. Due to the heteroge-
neity of CD, it is necessary to select a suit-
able treatment strategy for different patient. 
Current data have shown that age stratifica-
tion, special patients, disease location and 
extension, genetic and serologic markers 
could be used as predictors of disease 
course. But little clinical trials are associat-
ed them with the two treatment strategies. 
In future, the management strategies to CD 
will be based on these predictors to evaluate 
therapeutic efficacies. The proposition of 
early CD provides a cue to determine when 
to start anti-TNF therapy or combination 
with immunosuppressives. This need more 
evidence to support. Furthermore, Lémann 
score (a tissue damage score) should be 
considered for a further study and be putted 
into widely use in CD to assess adequately 
the ability of treatment strategies to change 
natural history. Despite use of a traditional 
step-up therapy may has better the risk-
benefit and cost-effectiveness ratio in the 
short term, most CD patients eventually re-
quire surgery at some time in their disease 
course. But new top-down therapy has re-
markably achieving a long time efficacies. 
Therefore, further studies should pay more 
attention to the long-term benefits. Medical 
therapy is not the only treatment in CD, 
surgery, vaccine, LCAP and stem cell ther-
apy are all effective therapeutic approaches 
which some of them are understudy. This 
lead to a further direction of changing the 
two classic paradigms: 
1) Optimizing the traditional step-up ap-
proach by combination with vaccine. 
2) Changing the top-down approach by ear-
ly use of LCAP and stem cell therapy 
and re-evaluation of surgical timing. 
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